Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 566 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alcohol administration; Placebo administration Clear all
Completed Phase 4 Interventional

Optimizing Electroconvulsive Therapy for Depression

NCT00045916
View directory record Official record
Conditions
Depression, Depressive Disorder, Bipolar Disorder
Interventions
High dosage electroconvulsive therapy, Nortriptyline, Venlafaxine, Lithium, Low dosage electroconvulsive therapy
Procedure · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biomarkers to Measure Treatment Response for Alcohol Dependence

NCT02315885
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Alcohol administration; Placebo administration
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT00665600
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Levalbuterol HCl, Albuterol Sulfate, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years to 99 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
20
States / cities
Carmichael, California • Spring Valley, California • Wheat Ridge, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects

NCT00329407
View directory record Official record
Conditions
Alcoholism
Interventions
Topiramate (Topamax)
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy

NCT04332211
View directory record Official record
Conditions
Barotrauma;Ear
Interventions
Hyperbaric Oxygen Therapy, Pseudoephedrine 60 MG, Placebo oral tablet
Procedure · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Phase 2 Interventional Results available

Exploration of Gemfibrozil as a Treatment for AUD

NCT03539432
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Gemfibrozil 600 MG, Placebo oral capsule
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 20, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms

NCT04782830
View directory record Official record
Conditions
Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Orthostatic; Hypotension, Parkinsonism
Interventions
Accelerometer, placebo pill, Midodrine or atomoxetine pill
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

NCT00640484
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), placebo, salmeterol
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

NCT02525718
View directory record Official record
Conditions
Breast Cancer
Interventions
Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans

NCT00145210
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

NCT02031640
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate, Placebo, Albuterol/salbutamol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
94
States / cities
Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes

NCT01606787
View directory record Official record
Conditions
Renal Cancer
Interventions
mannitol, placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Novel Topical Therapies for the Treatment of Genital Pain

NCT02099006
View directory record Official record
Conditions
Female Genital Diseases
Interventions
Amitriptyline, Baclofen, Ketoprofen, Ketamine, Loperamide, Gabapentin, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 20, 2026, 4:04 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

NCT06484075
View directory record Official record
Conditions
Healthy Volunteers, Alcohol Use Disorder (AUD)
Interventions
Siemens 3T PRISMA MR Scanner, PET/CT Scanner, Suvorexant, Placebo
Device · Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

NCT00158093
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Atenolol, Moxifloxacin
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Not applicable Interventional

Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control

NCT02002806
View directory record Official record
Conditions
Pancreas Cancer, Biliary Tract Cancer
Interventions
Alcohol Injection, Placebo Injection
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

NCT02228408
View directory record Official record
Conditions
Chronic Hemodialysis (ESRD)
Interventions
Hydralazine/Isorsorbide Dinitrate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

NCT00611026
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine ER, Placebo, Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
102
States / cities
Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

NCT00806260
View directory record Official record
Conditions
Overweight, Obesity
Interventions
VI-0521, Placebo, Alcohol, alcohol placebo
Drug · Other
Lead sponsor
VIVUS LLC
Industry
Eligibility
21 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Hydrocortisone for BPD

NCT01353313
View directory record Official record
Conditions
Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Bronchopulmonary Dysplasia
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 30 Weeks
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Epinephrine in Endotoxemia in Normal Volunteers

NCT00753402
View directory record Official record
Conditions
Immune System
Interventions
Endotoxin, Lipopolysaccharide, LPS, Endotoxin, Epinephrine
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Study of Sunobinop on Craving in Alcohol Use Disorder

NCT06545929
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Sunobinop, Placebo to match sunobinop
Drug
Lead sponsor
Knoa Pharma LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

NINDS CRC Chronic Migraine Treatment Trial

NCT00772031
View directory record Official record
Conditions
Chronic Migraine
Interventions
propranolol LA, topiramate, placebo
Drug
Lead sponsor
Anne Lindblad
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Tuscon, Arizona • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 20, 2026, 4:04 AM EDT